• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Vandenberg Dairy 23-Jun-06

Department of Health and Human Services' logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration


Seattle District
Pacific Region
22201 23rd Drive SE
Bothell, WA 98021-4421
Telephone : 425-486-8788
FAX: 425-483-4998


June 23, 2006


In reply refer to Warning Letter SEA 06-34

William G. Vandenberg, Owner
Vandenberg Dairy
13503 Goodson Road
Caldwell, Idaho 83607


Dear Mr. Vandenberg:

An investigation of your dairy operation located at 13503 Goodson Road, Caldwell, Idaho, conducted by representatives of the U.S. Food and Drug Administration (FDA) on May 2 and 3, 2006, confirmed that you offered animals for sale for slaughter as food that were adulterated under sections 402(a)(2)(C)(ii) [21 U.S.C. 342 (a)(2)(C)(ii)] and 402(a)(4) [21 U.S.C. 342 (a)(4)j of the Federal Food, Drug, and Cosmetic Act (the Act). The inspection also revealed that you caused the new animal drug, Sulfadimethoxine, to become adulterated within the meaning of section 501(a)(5) [21 U.S.C. 351(a)(5)] and unsafe under section 512 of the Act [21 U.S.C 360b]. You can find the Act and its associated regulations on the Internet through links on the FDA's web page at www.fda.gov.

On or about January 3, 2006, you sold a dairy cow, identified with Back Tao Number 82DL 6954, for slaughter as food to [redacted] shipped the cow to [redacted]. On or about January 6, 2006, this animal was slaughtered at [redacted]. United States Department of Agriculture, Food Safety and Inspection Service (USDAIFSIS) analysis of tissue samples collected from that animal identified the presence of 5.3 parts per million (ppm) of sulfadimethoxine in the liver tissue, 2.34 ppm of sulfadimethoxine in muscle tissue, and 1.836 ppm of flunixin in the liver tissue. A tolerance of 0.1 ppm has been established for residues of sulfadimethoxine in the uncooked, edible tissues of cattle as codified in Title 21, Code of Federal Repulations. Section 556.640 (21 C.F.R. 556.640). A tolerance of 0.125 ppm has been established for residues of flunixin in the liver tissues of cattle as codified in 21 C.F.R. 556.286. The presence of these drugs in uncooked edible tissue above the established tolerance from this animal causes the food to be adulterated within the meaning of section 402(a)(2)(C)(ii) [(21 U.S.C. § 342(a)(2)(C)(ii)].

Our inspection also found that you hold animals under conditions that are so inadequate that medicated animals bearing potentially harmful drug residues are likely to enter the food supply. You lack an adequate system to ensure that animals medicated by you have been withheld from slaughter for appropriate periods of time to permit depletion of potentially hazardous residues of drugs from edible tissues. For example, our investigation disclosed that you could not locate treatment records for the entire year of 2005 and that treatment records maintained for 2006 did not include the dosage administered, withdrawal time, the date the animal may be released for slaughter, and some records did not include the name of the drug used and route of administration. Food from animals held under such conditions is adulterated within the meaning of section 402(a)(4) of the Act [21 U.S.C. 342 (a)(4)].

In addition, you adulterated the drug, Sulfadimethoxine, within the meaning of section 501(a)(5) [21 U.S.C. 351 (a)(5)] of the Act when you failed to use the drug in conformance with its approved labeling. "Extralabel use," i.e., the actual or intended use of a drug in an animal in a manner that is not in accordance with the approved labeling, is only permitted if the use is by or on the lawful order of a licensed veterinarian within the context of a valid veterinarian/client/patient relationship. The extraiabel use of approved veterinary or human drugs must comply with sections 512(a)(4) and 512(a)(5) [21 U.S.C. 360b(a)(4) and 21 U.S.C. 360b(a)(5)] of the Act and 21 C.F.R. Part 530. Our investigation found that your extralabel use of Sulfadimethoxine failed to comply with these requirements.

You administered the Suifadimethoxine without following the route of administration set forth in the approved labeling when you administered the drug intravenously, rather than orally, and you did so without the supervision of a licensed veterinarian, in violation of 21 C.F.R. 530.11(a). Furthermore, your extralabel use resulted in a drug residue above the established tolerances for this drug, in violation of 21 C.F.R. 530.11(d). Because your extralabel use of this drug was not in compliance with 21 CFR Part 530, the drug was unsafe under section 512(a) [21 U.S.C. 360b(a)] of the Act and your use caused it to be adulterated within the meaning of section 501(a)(5) [21 U.S.C. 351(a)(5)] of the Act.

We are aware of the following additional violative tissue residues, which USDA/FSIS has traced back and assigned to your farm.

USDAIFSIS Sample # SlaughterResidue(ppm)ITissue Tolerance(ppm)



00.98 sulfadimethoxine/liver

00.46 sulfadimethoxine/muscle





14.80 sulfadimethoxine/liver

20.90 sulfadimethoxinelmuscle





02.20 sulfadimethoxine/liver

01.60 sulfadimethoxine/muscle





06.30 sulfadimethoxine/liver

08.30 sulfadimethoxine/muscle





16.18 sulfadimethoxine/liver

18.28 sulfadimethoxine/muscle

05.80 oxytetracycline/muscle

16.00 oxytetracycline/kidney







01.40 sulfadimethoxine/muscle


The above is not intended to be an all-inclusive list of violations. As a producer of animals offered for use as food, you are responsible for ensuring that your overall operation and the food you distribute is in compliance with the law. You should take prompt action to correct the above violations and to establish procedures whereby such violations do not recur. Failure to do so may result in regulatory action without further notice such as seizure and/or injunction.

You should notify this office in writing of the steps you have taken to bring your firm into compliance with the law within fifteen (15) working days of receiving this letter. Your response should include each step that has been taken or will be taken to correct the violations and prevent their recurrence. If corrective action cannot be completed within fifteen (15) working days, state the reason for the delay and the time frame within which the corrections will be completed. Please include copies of any available documentation demonstrating that corrections have been made.

Please send your written reply to the Food and Drug Administration, Attention: Michael J. Donovan, Compliance Officer, 22201 23rd Drive SE, Bothell, Washington 98021-4421. If you have questions regarding any issue in this letter, please contact Mr. Donovan at (425) 483-4906.



Russell W. Gripp for Charles M. Breen
District Director
Charles M. Breen